Clinical and laboratory studies
The treatment of Sézary syndrome

https://doi.org/10.1016/S0190-9622(84)80323-0Get rights and content

The results of treatment programs were studied in forty patients with Sézary syndrome. Thirty-three patients died. The principal treatment was a low-dose chlorambucil and prednisone regimen. Patients so treated lived longer from diagnosis of erythroderma (median survival, 6.2 yr) than did patients on other regimens (median survival, 3.05 yr). The addition of x-ray or chemotherapeutic programs did not increase significant long-term benefit. Seven patients receiving chlorambucil and prednisone had remission (1 yr or more); most patients had partial remission, but two patients did not have a response to this program. The complications of sepsis, progressive disease, and lymphoma occurred both in patients who were and in those who were not treated with chlorambucil and prednisone. We believe that a regimen of low-dose chlorambucil and prednisone is satisfactory treatment that can be the basis for comparison of new therapeutic approaches to Sézary syndrome. (J AM ACRD DERMATOL 10:1000–1004, 1984.)

References (10)

There are more references available in the full text version of this article.

Cited by (52)

  • Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario

    2021, Anais Brasileiros de Dermatologia
    Citation Excerpt :

    Chlorambucil is an alkylating agent and forms cross-links in DNA, causing DNA damage and affecting replication and transcription. Chlorambucil can be used orally in a continuous regimen with 2–6 mg/day of chlorambucil plus 20 mg/d of prednisone, or in pulses of 10 to 12 mg/day of chlorambucil for 3 days and fluocortolone, with a dose of 75 mg on the first day, 50 mg on the second day and 25 mg on the third day, every two weeks.35,36 Doses and intervals can be reduced and prolonged as the disease improves.

  • Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma

    2015, Dermatologic Clinics
    Citation Excerpt :

    Winkelmann reported that SS patients lived twice as long with chlorambucil therapy and 10 of 17 patients had a decreased peripheral blood Sézary cell count. Seven of 19 SS patients had a CR for at least 1 year on chlorambucil/corticosteroid.44 Coors and colleagues43 used chlorambucil with corticosteroids (chlorambucil 10–12 mg for 3 days and fluocortolone, first day 75 mg, second day 50 mg, and third day 25 mg) twice monthly and reported a 100% ORR in 13 patients with erythrodermic disease (8 stage III, 4 stage IVA, and 1 stage IVB).

  • Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

    2011, Journal of the American Academy of Dermatology
    Citation Excerpt :

    In these open trials, all patients had skin and blood involvement and some had clinical evidence of nodal disease as well. Continuous treatment with chlorambucil (2-6 mg/d) in conjunction with prednisone (initially ∼20 mg/d, tapering over time) (regimen of Winkelmann et al169,224) resulted in a significant response in patients with SS.223 In the study reported by McEvoy et al,225 leukapheresis was also performed concurrently with an OR of 100% including two of 11 CR.

  • Primary Cutaneous Lymphomas

    2006, The Lymphomas
View all citing articles on Scopus
View full text